Impact of levothyroxine on erectile function measured by the IIEF-15, EHS, PGIC and EDITS questionnaires in patients with hypothyroidism. Prospective, randomized controlled clinical trial with sildenafil 100

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514789-38-00

Acronym

457531

Enrollment

Registered

2024-09-30

Start date

Unknown

Completion date

2025-12-01

Last updated

2024-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

erectile function, hypothyroidism subclinic

Brief summary

The evolution of the scores measured by the IIEF-15, EHS, PGIC and EDITS questionnaires throughout the baseline measurements, and at the 3-month post-treatment follow-up in the three study groups after the start of treatment

Interventions

DRUGSILDENAFIL

DRUGLEVOTHYROXINE SODIUM

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The evolution of the scores measured by the IIEF-15, EHS, PGIC and EDITS questionnaires throughout the baseline measurements, and at the 3-month post-treatment follow-up in the three study groups after the start of treatment	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026